Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.
Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. Ray A, et al. Among authors: meek sm. Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453. Oncotarget. 2016. PMID: 27391442 Free PMC article. Clinical Trial.
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Dubsky PC, et al. Among authors: meek sm. Eur J Cancer. 2020 Jul;134:99-106. doi: 10.1016/j.ejca.2020.04.020. Epub 2020 Jun 2. Eur J Cancer. 2020. PMID: 32502940 Free article. Clinical Trial.
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Constantinidou A, Marcou Y, Toss MS, Simmons T, Bernhisel R, Hughes E, Probst B, Meek S, Kakouri E, Georgiou G, Zouvani I, Savvidou G, Kuhl V, Doedt J, Wagner S, Gutin A, Slavin TP, Lanchbury JS, Kronenwett R, Ellis IO, Rakha EA. Constantinidou A, et al. Clin Cancer Res. 2022 Oct 14;28(20):4435-4443. doi: 10.1158/1078-0432.CCR-22-0619. Clin Cancer Res. 2022. PMID: 36043530 Free PMC article.
Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, Gallagher S, Meek S, Dalton K, Hedegard W, Adami CA, Grear DF, Domchek SM, Garber J, Lancaster JM, Weitzel JN, Kurian AW, Lanchbury JS, Gutin A, Robson ME. Hughes E, et al. Among authors: meek s. JCO Precis Oncol. 2021 Jan 28;5:PO.20.00246. doi: 10.1200/PO.20.00246. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036224 Free PMC article.
Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model.
Gallagher S, Hughes E, Kurian AW, Domchek SM, Garber J, Probst B, Morris B, Tshiaba P, Meek S, Rosenthal E, Roa B, Slavin TP, Wagner S, Weitzel J, Gutin A, Lanchbury JS, Robson M. Gallagher S, et al. Among authors: meek s. JCO Precis Oncol. 2021 Jun 24;5:PO.20.00484. doi: 10.1200/PO.20.00484. eCollection 2021 Jun. JCO Precis Oncol. 2021. PMID: 34322652 Free PMC article.
Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Kuhl V, Clegg W, Meek S, Lenz L, Flake DD 2nd, Ronan T, Kornilov M, Horsch D, Scheer M, Farber D, Zalaznick H, Cussenot O, Compérat E, Cancel-Tassin G, Wild PJ, Chun FK, Mandel P, Moinfar F, Cohen T, Delee S, Kronenwett R, Doedt J. Kuhl V, et al. Biomark Med. 2022 Apr;16(6):449-459. doi: 10.2217/bmm-2021-0479. Epub 2022 Mar 24. Biomark Med. 2022. PMID: 35321552 Free article.
16 results